Posted by Michael Wonder on 21 Dec 2022
European Commission approves Eladynos (abaloparatide) for the treatment of osteoporosis in post-menopausal women at increased risk of fracture
19 December 2022 - Radius Health announced that the European Commission has granted marketing authorisation for abaloparatide under the trade name of Eladynos to treat osteoporosis in postmenopausal women at increased risk of fracture.
Abaloparatide has been approved in the US since April 2017 under the trade name of Tymlos.
